Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00107393
Status:
COMPLETED
Last Update Posted:
2013-07-10
First Post:
2005-04-05
Brief Title:
Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer
Sponsor:
Tohoku University
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase II Study of Trastuzumab Herceptin and Capecitabine Xeloda in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression
Status:
COMPLETED
Status Verified Date:
2006-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Monoclonal antibodies such as trastuzumab can block tumor growth in different ways Some block the ability of tumor cells to grow and spread Others find tumor cells and help kill them or carry tumor-killing substances to them Drugs used in chemotherapy such as capecitabine work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing Giving trastuzumab together with capecitabine may kill more tumor cells
PURPOSE This phase II trial is studying how well giving trastuzumab together with capecitabine works in treating women with metastatic breast cancer
PURPOSE This phase II trial is studying how well giving trastuzumab together with capecitabine works in treating women with metastatic breast cancer
Detailed Description:
OBJECTIVES
Primary
Determine the median survival time and 2-year survival rate in women with taxane- and anthracycline-refractory HER2neu-overexpressing metastatic breast cancer treated with trastuzumab Herceptin and capecitabine
Secondary
Determine the progression-free survival of patients treated with this regimen
Determine the response rate in patients treated with this regimen
Determine the clinical benefit rate of this regimen in these patients
Determine the safety profile of this regimen in these patients
OUTLINE This is a multicenter study Patients are stratified according to prior treatment with trastuzumab Herceptin yes vs no HER2neu status 3 by immunohistochemistry vs positive by fluorescence in situ hybridization and class of refractory disease primary vs secondary vs treatment discontinuation due to adverse events
Patients receive oral capecitabine once daily on days 1-21 and trastuzumab IV on days 1 8 15 and 22 Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
After completion of study treatment patients are followed for up to 2 years
PROJECTED ACCRUAL A total of 75 patients will be accrued for this study within 3 years
Primary
Determine the median survival time and 2-year survival rate in women with taxane- and anthracycline-refractory HER2neu-overexpressing metastatic breast cancer treated with trastuzumab Herceptin and capecitabine
Secondary
Determine the progression-free survival of patients treated with this regimen
Determine the response rate in patients treated with this regimen
Determine the clinical benefit rate of this regimen in these patients
Determine the safety profile of this regimen in these patients
OUTLINE This is a multicenter study Patients are stratified according to prior treatment with trastuzumab Herceptin yes vs no HER2neu status 3 by immunohistochemistry vs positive by fluorescence in situ hybridization and class of refractory disease primary vs secondary vs treatment discontinuation due to adverse events
Patients receive oral capecitabine once daily on days 1-21 and trastuzumab IV on days 1 8 15 and 22 Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
After completion of study treatment patients are followed for up to 2 years
PROJECTED ACCRUAL A total of 75 patients will be accrued for this study within 3 years
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000380787 | REGISTRY | PDQ Physician Data Query | None |